Farma

Computum
08.05.2020 kl 16:07 2832

Strong 1Q results in line with company‘s guidance

NattoPharma delivered 1Q20 results in line with our expectations and the company‘s guiding. The record-strong quarter for the company was marked by high volumes and improved cost efficiency. Thus, we revised our revenue growth expectations upwards and increased EBITDA margins going forward which lead to a higher target price of NOK 19/sh (prev. NOK 14/sh). Buy recommendation is maintained as we continue to believe in strong vitamin K2 growth potential and company‘s focus on operational improvements. (Norne)
Redigert 21.01.2021 kl 06:06

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.